FDA Approves xT CDx, a NGS-Based in Vitro Diagnostic Device

The FDA has approved xT CDx, a 648-gene next-generation sequencing assay for solid tumor profiling, and companion diagnostic for patients with colorectal cancer.

Related Keywords

Eric Lefkofsky ,Tempus Labs Inc , ,Companion Diagnostics ,Xt Cdx ,Rings ,Next Generation Sequencing ,Diagnostic Device ,Colorectal Cancer ,Cetuximab ,Erbitux ,Panitumumab ,Vectibix ,